TuHURA Biosciences (HURA) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of TuHURA Biosciences (NASDAQ: HURA) recently:

• 4/27/2026 – TuHURA Biosciences is now covered by Citigroup Inc.. They set an “outperform” rating on the stock.
• 4/27/2026 – TuHURA Biosciences is now covered by Citizens Jmp. They set a “market outperform” rating and a $9.00 price target on the stock.
• 4/25/2026 – TuHURA Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/21/2026 – TuHURA Biosciences had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 4/15/2026 – TuHURA Biosciences is now covered by Rodman & Renshaw. They set a “buy” rating on the stock.
• 4/15/2026 – TuHURA Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.
• 4/7/2026 – TuHURA Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/30/2026 – TuHURA Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/22/2026 – TuHURA Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/14/2026 – TuHURA Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.